Background: Although cognition is known to impact clinical symptoms of schizophrenia, few studies investigate the potential mediators of this relationship. This study aimed to examine the relationship between cognitive deficits and negative symptoms in schizophrenia, considering the mediating role of alexithymia as an important psychological variable. Moreover, the prevalence of alexithymia in patients with schizophrenia was investigated.
Methods: A total of 689 patients with schizophrenia were recruited from two psychiatric hospitals. All patients completed the Positive and Negative Syndrome Scale (PANSS), 20-item Toronto Alexithymia Scale (TAS-20), and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). We used structural equation modeling to examine the hypothesized mediated model.
Results: In total, 31.5 % of patients with schizophrenia were classified as alexithymia. The path analyses showed that two factors of alexithymia (i.e., the difficulty in identifying feelings and difficulty in describing feelings), played a mediating role in the pathway from cognitive deficits to negative symptoms (all p < .001).
Limitations: Self-reported measurement for alexithymia may not be sufficiently reliable due to response bias.
Conclusion: Our findings demonstrated a high occurrence of alexithymia in patients with schizophrenia. Moreover, the mediating role of alexithymia suggests that targeting emotion processing and cognition may be a feasible way to mitigate negative symptoms.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.schres.2023.10.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Identification of (PDZ-RhoGEF) as an in vivo regulator of synapses and cognition.
Proc Natl Acad Sci U S A
January 2025
Department of Comparative Biosciences, University of Wisconsin-Madison, Madison, WI 53706.
Given the influence of cognitive abilities on life outcomes, there is inherent value in identifying genes involved in controlling learning and memory. Further, cognitive dysfunction is a core feature of many neuropsychiatric disorders. Here, we use a combinatory in silico approach to identify human gene targets that will have an especially high likelihood of individually and directly impacting cognition.
View Article and Find Full Text PDFAssociation Between Oral Health Status and DMFT Index with Cognitive Dysfunction in Community-Dwelling Older Adults with Type 2 Diabetes: A Cross-Sectional Study.
Exp Aging Res
January 2025
Dental Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
Objective: Cognitive dysfunction is a significant issue in old age and can cause many problems in older adults, especially those with diabetes. This study aimed to investigate the association between oral health status and DMFT index with cognitive dysfunction in community-dwelling older adults with T2D (type 2 diabetes).
Methods: This was a cross-sectional study that included 245 older people aged 60 years and older with T2D, visiting healthcare centers in north of Iran, using the cluster sampling method.
Early detection and management of hearing loss to reduce dementia risk in older adults with mild cognitive impairment: findings from the treating auditory impairment and cognition trial (TACT).
Age Ageing
January 2025
Division of Psychiatry, University College London, London, UK.
Background: Age-related hearing loss and mild cognitive impairment (MCI) independently increase dementia risk. The Ageing and Cognitive Health Evaluation in Elders randomised controlled trial (RCT) found hearing aids reduce cognitive decline in high-risk older adults with poor hearing.
Methods: This pilot RCT in London memory clinics randomised people with MCI (aged ≥55, untreated hearing loss defined as Pure Tone Average 0.
Auranofin-loaded PLGA Nanoparticles for Neuroprotection against Aluminium-induced Alzheimer's Disease.
Curr Pharm Des
January 2025
Maharaja Ranjit Singh Punjab Technical University Pharma Innovation Lab, Department of Pharmaceutical Sciences & Technology Bathinda India.
Aim: The aim of the current study was to explore nano-formulation for effective neuroprotection by auranofin.
Background: Currently, the treatment options for various CNS disorders, particularly neurodegenerative disorders, are greatly constrained. A significant obstacle in this pursuit is the blood-brain barrier, a shielding covering that hinders the route of numerous biochemical treatments into the brain.
Neuropsychological outcome of indoor rehabilitation in post-COVID-19 condition-results of the PoCoRe study.
Front Neurol
January 2025
Department of Psychosomatic Medicine, University Hospital Regensburg, Regensburg, Germany.
Background: Post COVID-19 condition (PCC) is increasingly recognized as a debilitating condition characterized by persistent symptoms following SARS-CoV-2 infection. Neuropsychological deficits, including cognitive impairments and fatigue, are prevalent in individuals with PCC. The PoCoRe study aimed to evaluate the burden of neuropsychological deficits in PCC patients undergoing multidisciplinary indoor rehabilitation and to describe possible changes in this symptomatology.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!